ANTI-VEGF ANTIBODIES AND APPLICATIONS THEREOF Russian patent published in 2015 - IPC C07K16/22 C07K19/00 A61K39/395 A61P35/00 A61P37/00 A61P27/02 

FIELD: medicine, pharmaceutics.

SUBSTANCE: inventions refer to biotechnology. Presented are: variants of a monoclonal anti-VEGF antibody or its antigen-binding fragment, which are characterised by the fact that they contain 6 CDRs and optionally T51A substation in CDR-L2, and also have one or a combinations of substitutions as compared to the antibody bevacizumab, namely: 1. K64S in CDR-H2; 2. K64Q in CDR-H2; 3. Y53F and K64Q in CDR-H2; 4. Y53F and K64S in CDR-H2; 5. H97E in CDR-H3; 6. Y98F in CDR-H3; 7. H97E and Y98F in CDR-H3; 8. H97P and Y98F in CDR-H3. Described are: a conjugate of the antibody and a medicinal product neutralising VEGF activity based on the antibody or its antigen-binding fragment; a pharmaceutical composition also based on the antibody or its antigen-binding fragment, or the conjugate, which neutralizes VEGF activity. Disclosed are a method of treating a cancer disease, and also a method of treating age-related macular degeneration or an immune disorder on the basis of the above antibody or its antigen-binding fragment, or the conjugate.

EFFECT: using the invention provides the new variants of the anti-VEGF antibody or its antigen-binding fragment exhibiting lower immunogenic activity as compared to bevacizumab.

26 cl, 4 dwg, 20 tbl, 3 ex